menu
    • menu
    [{"orgOrder":0,"company":"Upstream Bio","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2023","type":"Series B Financing","leadProduct":"UPB-101","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream Bio","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.20000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Upstream Bio \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Upstream Bio \/ Enavate Sciences"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"UPB-101","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Upstream Bio \/ Not Applicable"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Verekitug","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Not Applicable"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Verekitug","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Upstream Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Upstream Bio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Upstream Bio \/ Not Applicable"},{"orgOrder":0,"company":"Upstream Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Verekitug","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Upstream Bio","amount2":0.26000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Upstream Bio \/ J.P. Morgan","highestDevelopmentStatusID":"14","companyTruncated":"Upstream Bio \/ J.P. Morgan"}]

    Find Clinical Drug Pipeline Developments & Deals by Upstream Bio

    Menu

    Upstream Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verekitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $255.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Upstream Bio Announces Pricing of Upsized Initial Public Offering

                            Details : The proceeds will advance UPB-101 (verekitug) through the completion of a multi-national, placebo-controlled, randomized Phase 2 in severe asthma, and to initiate subsequent Phase 3 development.

                            Brand Name : UPB-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 10, 2024

                            Lead Product(s) : Verekitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : J.P. Morgan

                            Deal Size : $255.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verekitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Upstream Bio Starts Phase 2 Trial of Verekitug in Severe Asthma, Dosing First Patients

                            Details : Upstream Bio's investigation product UPB-101 (verekitug), a TLSPR inhibitor, which is being evaluated in Phase II clinical trial studies for patients with severe asthma.

                            Brand Name : UPB-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 07, 2024

                            Lead Product(s) : Verekitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verekitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Upstream Bio Announces Dosing Of First Patients in Phase 2 Trial Of Verekitug

                            Details : UPB-101 (verekitug) is a fully human immunoglobulin G1 antibody designed to block the thymic stromal lymphopoietin receptor, under phase 2 clinical for Chronic Rhinosinusitis with Nasal Polyps.

                            Brand Name : UPB-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 03, 2024

                            Lead Product(s) : Verekitug

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UPB-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2

                            Details : UPB-101 is a novel recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to the human thymic stromal lymphopoietin (TSLP) receptor (TSLPR) to inhibit signaling. UPB-101 is designed to address allergic and inflammatory dise...

                            Brand Name : UPB-101

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 24, 2023

                            Lead Product(s) : UPB-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Upstream Bio

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : UPB-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Enavate Sciences

                            Deal Size : $200.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases

                            Details : The net financing will be used to support the future development of UPB-101, a monoclonal antibody targeting the TSLP receptor, in asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

                            Brand Name : UPB-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 08, 2023

                            Lead Product(s) : UPB-101

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Enavate Sciences

                            Deal Size : $200.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth